Tianjin Lisheng Pharmaceutical

Tianjin Lisheng Pharmaceutical is a leading Chinese pharmaceutical company with an extensive portfolio of approved small molecule and biologic drugs, particularly recognized for its cardiovascular, endocrine, and anti-infective products. The company integrates R&D, API manufacturing, finished formulation, and CMO services, and has received multiple national recognitions for product quality and historic brand value. Recent clinical and regulatory achievements include approvals for indapamide sustained-release tablets and rivaroxaban tablets, as well as consistency evaluation certification for hydrocortisone sodium succinate for injection.